Medical/Pharmaceuticals

LEADING WITH HEART - The Women of PHKL Shaping the Future of Healthcare

KUALA LUMPUR, Malaysia, March 7, 2025 /PRNewswire/ -- Healthcare is more than science—it is compassion, resilience, and an unwavering commitment to healing. Behind every life saved and every family given hope, there are extraordinary individuals who dedicate themselves to the well-being of others...

2025-03-07 13:50 4220

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pemb...

2025-03-07 13:03 2201

THE BRACCO GROUP: OFFICIAL GOLD SPONSOR OF THE ITALY PAVILION AT THE OSAKA EXPO 2025

At the Japanese World Expo, to be held from April 13 to October 13, 2025, the Bracco Group will be a key contributor on the themes of art, technology and medicine of the future. In addition to several scientific events organized by Bracco Japan, a ballet by the La Scala Academy onItaly's National...

2025-03-07 07:30 2965

NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'

Pioneering a Paradigm Shift in Pain Treatment, Accelerating Global Market Expansion SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable microsphere for muscu...

2025-03-06 22:00 2987

Lunit Expands Partnership with Saudi Arabia's Largest Medical Group to Deploy AI Chest X-Ray Solution

Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...

2025-03-06 22:00 3594

GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy

SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has receivedclearance from the U.S Food and Drug Administration(FDA) for its Investigational...

2025-03-06 17:00 1881

Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine

* The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. * In preclinical studies, EVM16 demonstrated...

2025-03-06 16:30 2434

Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics

SINGAPORE, March 6, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape inSingapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to formArcherfish Precision Diagnostics Private Limited (...

2025-03-06 11:52 2158

Docquity's AI Platform Enhances Medical Knowledge and Patient Care at RSUD Umar Wirahadikusumah Sumedang

* Dx, Docquity's AI platform which is in ongoing development, will enable physicians at the Sumedanghospital to securely access the latest medical research for stronger treatment decisions * The collaboration follows Sumedang Regency's introduction of Docquity's AI platform for greater public...

2025-03-06 10:00 4107

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibod...

2025-03-06 08:30 2347

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

* Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. * CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor...

2025-03-06 08:10 2465

Suvoda launches Sofia, a new AI assistant to simplify management of clinical trials

From many clicks to one query, drug supply managers can more quickly access, analyze, and visualize the trial supply data they need. PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like on...

2025-03-05 23:17 2099

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma ...

2025-03-05 22:45 1978

Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director

ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend) , a gene to GMP advanced therapy development partner, today announced the appointment ofJohn Chiminski and Karen Flynn as non-executive members of its Board of Directors. John will ser...

2025-03-05 22:33 2569

Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics

SINGAPORE, March 5, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape inSingapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to formArcherfish Precision Diagnostics Private Limited (...

2025-03-05 22:00 2511

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

HIGHLIGHTS * Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. * Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC...

2025-03-05 21:44 2816

SanyouBio Launches 73 Whole-Series Bispecific Reference Antibody Products, Facilitating New Breakthroughs in Bispecific Drug Development

SHANGHAI, March 5, 2025 /PRNewswire/ -- SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative clinical-stage bispecific antibody drugs. The launch of this product series will provide robust support fo...

2025-03-05 20:00 2095

CQ Medical's Iris AirShuttle™ Patient Transfer Platform Recognized at Women in Innovation Award Showcase

AVONDALE, Pa., March 5, 2025 /PRNewswire/ -- The Iris AirShuttle™, a patient transfer platform developed by CQ Medical, is designed to streamline the transfer of patients from procedures to imaging. Recently, it was featured at theWomen in Innovation Award Showcase, an event that celebrated Profe...

2025-03-05 18:00 1578

Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL

BOSTON, March 5, 2025 /PRNewswire/ -- Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stagebiotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) appli...

2025-03-05 14:49 2030

CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland

* CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities acrossEurope and the US. * In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to lar...

2025-03-05 13:30 2364
1 ... 124125126127128129130 ... 644